We would love to hear your thoughts about our site and services, please take our survey here.
Things are becoming so predictable here I am beginning to think I should started trading it!!
It will be a landmark approval and I can't believe CF won't shout it from the tree tops!
Just wondering when we are likely to hear about MHRA approval for the Covid challenge study, thoughts?
Also, we and the market already knew the Prep news released in the RNS today - remember the in depth discussions we had about it last week?? So the RNS 'old news' was never going to have a major impact IMHO.
DJ - agree and so does the market - steady decline in SP over the last 3 months now - proof and pudding!!
Agreed. Perhaps we should ask Ryan how they intend to fund a Ph2b study??
"We are excited about these new data allowing us to dose PrEP-001 daily for up to 12 weeks which is the expected length of a typical cold & flu season. We intend to move forward with a field trial to assess the efficacy against a number of common respiratory viruses and provide real world validation of PrEP-001 as a novel pan-viral prophylaxis," said Ryan Muldoon, CEO of PrEP Biopharm Limited.
JH - just reiterating whats stated in the announcement. A Phase 2b study is going to cost them in the order of $7-10M. Perhaps some of the OO capital will be invested in that study??
Ryan Muldoon - states that they intend to move forward with the Ph2b study - so who knows!
Thanks Eskers, more detail here.
https://www.prnewswire.com/news-releases/prep-biopharm-limited-announces-successful-completion-of-prep-001-toxicology-study-enabling-phase-2b-field-study-of-prep-001-against-all-respiratory-viruses-301194520.html
Moni - I hope they are all nicely tucked up in your ISAs ;)!
In all honesty the article doesn't say that the Codagenix study is a challenge study, it says that the companies have not shared that info - if they had looked on Clintrials.gov they would have got there answer . It does say that OO are planning to start both the IN Codagenix study and a challenge study in January. It would be great to get confirmation that the challenge studies have got MHRA approval - that should shift the SP!!!
'While the companies have not shared if this trial would be part of Open Orphan’s human challenge trials, the company is preparing to begin testing the method in January as well. The controversial trial method is said, by advocates, to be a quicker and safe method of testing a vaccine.'
Hi Czarboy - would be interested in your view on Flu-V and why it has been sat on the shelf for a couple of years now - pending a Phase 3 study start - any opinion??
Desert - take a look at Clintrials.gov, it describes the Codagenix study in detail - it isn't a challenge study. We have not yet received MHRA approval for the challenge studies.
Well that article is clearly wrong wrt a challenge study . The Codagenix study is a standard Phase 1 study, no mention of a challenge component.
Big MJ - me too. I guess we fell off the radar given that things have been a bit 'quiet' over the last number of months. Lets hope we LTH's get our due rewards for the years of patience!!
Where?? Don't think that's been approved yet???
NST-1, I was in BRH and you are correct that there was real confusion (ignorance really) on whether or not selling on ex-Divi day forfeited the divi - which I can categorically say it doesn't. That confusion lead to holders not selling yesterday at a really good price in the 20's and that together with the divi, making a really healthy profit.
Also some idiots bought in yesterday, thinking that they would qualify for the divi, which of course they won't - so that also bolstered the share price.
BRH then issued an RNS, after hours stating that 2 of the directors had sold off a load of shares yesterday - surprise, surprise!! Share price will likely fall to circa 12p. DYOR
I honestly don't understand why anyone holding at opening this morning did not sell in the 20's. This will fall to circa 12p today or tomorrow - then buy back in if you believe in the company. Well that's my strategy anyhow. GLA and DYOR.